China IIT, Daichi Sankyo-AZ, Leo-Tanabe—Fierce Pharma Asia
China IIT, Daichi Sankyo-AZ, Leo-Tanabe—Fierce Pharma Asia
AstraZeneca
AstraZeneca is a global biopharmaceutical company developing and commercializing medicines across oncology, cardiovascular, renal, metabolism, and respiratory diseases. The company has a deep and diversified late-stage pipeline including Tagrisso, Imfinzi, Enhertu, Calquence, and Farxiga, with multiple Phase 3 readouts and launches scheduled for 2026 across multiple therapeutic areas.
Company Info
Sector:Pharmaceutical / Diversified Biopharma
Headquarters:Cambridge, United Kingdom
Founded:1999
Website:www.astrazeneca.com/
Upcoming Milestones & Key Dates
Q3 2026
Earnings
H1 2026 earnings and pipeline update
H2 2026
Clinical Trial
Multiple Phase 3 readouts across oncology and rare-disease franchises
H2 2026
Regulatory
FDA advisory committee for SPAC-backed biotech on Nasdaq and pediatric bone-disease program update
Clinical Development Pipeline
Tagrisso (osimertinib) + chemotherapy
Target: Third-generation EGFR TKIEnhertu (trastuzumab deruxtecan)
Target: HER2-directed antibody-drug conjugate (DXd payload)Ultomiris (ravulizumab)
Target: Anti-C5 monoclonal antibody (long-acting)Recent News
AstraZeneca cans late-stage bispecific trial after lung cancer setback
Endpoints News reports AstraZeneca discontinued its late-stage volrustomig bispecific trial after a lung cancer efficacy setback.
AstraZeneca touts separate late-stage lung cancer wins with Tagrisso, Enhertu
Endpoints News reports AstraZeneca announced separate late-stage lung cancer trial wins for Tagrisso and Enhertu, distinct from its volrustomig bispecific setback the same day.
ICER says AstraZeneca’s new blood pressure med isn’t cost-effective
Endpoints News reports the Institute for Clinical and Economic Review (ICER) found AstraZeneca's new blood pressure medication not cost-effective at list price.
AstraZeneca, CSPC to form manufacturing joint venture
AstraZeneca and China's CSPC Pharmaceutical Group are forming a biologics manufacturing joint venture.
AstraZeneca, Bristol Myers in talks about merger — report
AstraZeneca and Bristol Myers Squibb are in merger talks per the Financial Times; AZ is worth roughly $265B and BMS about $133B, and the talks may not lead to a deal.
‘Unlikely’ AstraZeneca-BMS mega-merger would be largest pharma deal ever
‘Unlikely’ AstraZeneca-BMS mega-merger would be largest pharma deal ever
AstraZeneca has no plans to ramp up dealmaking in wake of Wainua failure
AstraZeneca has no plans to ramp up dealmaking in wake of Wainua failure.
AstraZeneca looks to AI to ease risk in late-stage trials, speed up filings
AstraZeneca looks to AI to ease risk in late-stage trials, speed up filings.
AZ leans on cancer muscle in solid Q2
AZ leans on cancer muscle in solid Q2.
AZ ‘very confident’ in homegrown ADCs despite dropping 2 assets
AZ ‘very confident’ in homegrown ADCs despite dropping 2 assets.
Wainua flop narrows AstraZeneca's path to $80B goal ahead of high-risk readouts
With a Phase 3 failure denting the rare disease drug's prospects, AstraZeneca has little room for error as it plots a path toward its ambitious 2030 sales target.
AstraZeneca buys lung cancer drug Zegfrovy from Dizal for $1.5B
AstraZeneca buys lung cancer drug Zegfrovy from Dizal for $1.5B
AstraZeneca, Ionis drug fails big heart disease study in major setback
AstraZeneca, Ionis drug fails big heart disease study in major setback
AstraZeneca takes another China trip, picking Dizal’s lung cancer drug for up to $1.5B
Dizal Pharmaceutical’s Zegfrovy is approved in the U.S. for locally advanced or metastatic non-small cell lung cancer. For $600 million upfront, AstraZeneca will gain global rights to advance and commercialize the asset.
AstraZeneca's Wainua fails key heart disease trial, shares tumble
AstraZeneca's Wainua fails key heart disease trial, shares tumble
AstraZeneca pens $2.1B deal for challenger to Merck’s Ohtuvayre
AstraZeneca pens $2.1B deal for challenger to Merck’s Ohtuvayre (reported by Fierce Biotech)
AstraZeneca pays CSPC $30M to form kidney drug discovery pact
AstraZeneca pays CSPC $30M to form kidney drug discovery pact — Fierce Biotech coverage of biopharma industry developments.
After landmark deal, AstraZeneca goes to CSPC again in up to $1.7B pact
After landmark deal, AstraZeneca goes to CSPC again in up to $1.7B pact — Endpoints News coverage of biopharma industry developments.
Phase 3 Failure Keeps AstraZeneca and Ionis Out of a Growing Heart Disease Market
Phase 3 Failure Keeps AstraZeneca and Ionis Out of a Growing Heart Disease Market
Biotech SPAC deal gets it to Nasdaq; AstraZeneca Phase 3 win in children's bone disease
Endpoints News covers a SPAC-backed biotech that has reached the Nasdaq, alongside AstraZeneca's Phase 3 win in a rare children's bone disease.
Leadership Team
Pascal Soriot
Chief Executive Officer
Aradhana Sarin
Chief Financial Officer
Dr. Susan Galbraith
Executive Vice President, Oncology R&D